NF2-related schwannomatosis
MONDO:0007039A tumor-prone disorder characterized by the development of multiple schwannomas and meningiomas.
Also known as: acoustic neurofibromatosis, NF2, NF2-related schwannomatosis, SWNV, bilateral acoustic neurofibromatosis, central neurofibromatosis, full NF2, full neurofibromatosis type 2
52 clinical trials for this condition and its sub-types, 21 tagged with NF2-related schwannomatosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New platform trial takes on NF2 tumors with multiple drug strategies
Disease control Not yet recruitingThis trial tests several drugs in people with NF2-related schwannomatosis, a condition that causes tumors on nerves and in the brain. The study uses a flexible 'platform' design to evaluate treatments for four tumor types: vestibular schwannomas, non-vestibular schwannomas, menin…
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
Disease control Not yet recruitingThis trial tests the drug selumetinib in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves, often leading to hearing loss. The study includes both adults and children whose tumors cannot be surgically removed or are growing. R…
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Drug combo aims to shrink NF2 tumors and save hearing
Disease control Not yet recruitingThis trial tests whether combining two drugs—luvometinib (a targeted therapy) and serplulimab (an immunotherapy)—can shrink tumors and improve hearing in people with NF2-related schwannomatosis. Participants have progressive vestibular schwannomas or meningiomas that are not suit…
Phase 1/2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New pill aims to shrink tumors in rare nerve disorder
Disease control Not yet recruitingThis early-phase trial tests an oral drug called Trineumin (PRG-N-01) in 25 adults with neurofibromatosis type II (NF2), a genetic condition that causes non-cancerous tumors on nerves. The study has two parts: first finding a safe dose, then checking if that dose can shrink tumor…
Phase 1/2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Rewiring the brain to silence chronic pain — a bold psychological therapy is put to the test
Symptom relief Not yet recruitingThis trial tests whether pain reprocessing therapy (PRT) — a brief psychological treatment that combines education, cognitive restructuring, and body-focused techniques — can reduce chronic pain. Adults with persistent pain lasting over three months are randomly assigned to full …
Sponsor: Ben-Gurion University of the Negev • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Patients and staff team up to redesign hospital clinics for sensory needs
Knowledge-focused Not yet recruitingThis project at King's College London asks how hospital outpatient departments can work better for people with neurofibromatosis who also have sensory challenges. About 30 patients, carers, and staff from Guy's and St Thomas' NHS Foundation Trust take part in interviews, observat…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New online tool aims to help families uncover hidden cancer risks
Knowledge-focused Not yet recruitingThis study tests whether a new online program can help families understand their inherited cancer risk and encourage relatives to get low-cost genetic testing. Researchers will enroll 400 adults who carry a cancer-related gene change and their family members. The goal is to see i…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC